Edition:
India

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

14,407.00ZAc
3 Jul 2020
Change (% chg)

-187.00 (-1.28%)
Prev Close
14,594.00
Open
14,594.00
Day's High
14,706.00
Day's Low
14,399.00
Volume
454,184
Avg. Vol
1,957,506
52-wk High
16,514.00
52-wk Low
6,407.00

Latest Key Developments (Source: Significant Developments)

UK's CMA Provisionally Finds Aspen Paid Firms To Stay Out Of UK Market For Addison's Disease Drug
Thursday, 3 Oct 2019 

Oct 3 (Reuters) - UK's CMA::PROVISIONALLY FOUND THAT 3 DRUG FIRMS SIGNED "ILLEGAL AGREEMENT" THAT RESULTED IN SIGNIFICANT PRICE HIKES FOR AN ESSENTIAL MEDICINE.PROVISIONALLY FOUND THAT ASPEN "UNLAWFULLY" AGREED TO PAY AMILCO AND TIOFARMA TO STAY OUT OF UK MARKET FOR FLUDROCORTISONE ACETATE TABLETS.PROVISIONALLY FOUND TIOFARMA, AMILCO "COLLUDED WITH ASPEN" BY AGREEING TO STAY OUT OF UK MARKET SO ASPEN WAS SOLE SUPPLIER OF FLUDROCORTISONE.SHOULD CMA CONCLUDE THERE WAS AN INFRINGEMENT, ASPEN AGREED TO MAXIMUM PENALTY OF £2.1 MILLION; AMILCO & TIOFARMA HAVE MADE NO ADMISSION.ACCEPTED ASPEN'S OFFER OF COMMITMENTS TO RESOLVE CONCERN ON PURCHASE OF COMPETITOR FLUDROCORTISONE PRODUCT FROM TIOFARMA FOR SUPPLY IN UK.COMMITMENTS INCLUDE ASPEN OFFERING TO PAY NHS £8 MILLION, & ENSURING THAT, IN FUTURE, THERE WILL BE AT LEAST 2 SUPPLIERS OF FLUDROCORTISONE IN UK.  Full Article

Aspen Pharmacare Posts FY Normalised HEPS From Cont Ops Down 7%
Wednesday, 11 Sep 2019 

Sept 11 (Reuters) - Aspen Pharmacare Holdings Ltd ::GROUP FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2019.FY REVENUE FROM CONTINUING OPERATIONS INCREASED BY 1% TO R38.9 BILLION.FY NORMALISED HEADLINE EARNINGS PER SHARE FROM CONTINUING OPERATIONS DECREASED BY 7% TO 1 414.3 CENTS.NO DIVIDEND HAS BEEN DECLARED FOR YEAR ENDED 30 JUNE 2019.FY NORMALISED EBITDA FROM CONTINUING OPERATIONS DECREASED BY 2% TO R10.8 BILLION.H2 PERFORMANCE IN 2020 FY IS LIKELY TO BE STRONGER THAN IN H1 OF THAT YEAR.PERFORMANCE FOR 2020 FY TO BE BROADLY IN LINE WITH RESULTS REPORTED FOR 2019.INTENDS TO PURSUE COMMERCIAL OPPORTUNITY OF RECOMMENCING SALE OF HEPARIN TO THIRD-PARTY CUSTOMERS.  Full Article

Aspen Pharmacare Sees FY Total HEPS 1,224-1 283 Cents
Tuesday, 3 Sep 2019 

Sept 3 (Reuters) - Aspen Pharmacare Holdings Ltd ::TRADING STATEMENT.SEES FY REPORTED REVENUE GROWTH 0% TO 2.0%.SEES FY TOTAL NHEPS 1 433.6 TO 1 498.1 CENTS.SEES FY CER REVENUE GROWTH -3.0% TO 0%.SEES FY NHEPS FROM CONTINUING OPERATIONS 1 381.8 TO 1 442.5 CENTS.SEES FY TOTAL HEPS 1 224.0 TO 1 283.0 CENTS.SEES FY HEPS FROM CONTINUING OPERATIONS 1 203.7 TO 1 259.0 CENTS.  Full Article

Aspen Pharmacare Says Coronation Asset Management Increased Beneficial Interest In Co
Friday, 23 Aug 2019 

Aug 23 (Reuters) - Aspen Pharmacare Holdings Ltd ::CORONATION ASSET MANAGEMENT NOTIFIED COMPANY THAT IT HAS INCREASED ITS BENEFICIAL INTEREST IN SECURITIES OF COMPANY.CORONATION ASSET MANAGEMENT HOLDS 10.60% OF ORDINARY SHARE CAPITAL OF COMPANY, EFFECTIVE 23 AUGUST.  Full Article

Aspen Pharmacare Announces Divestment Of Portfolio Of Prescription And OTC Products In Australia To Mylan
Monday, 20 May 2019 

May 20 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN’S DIVESTMENT OF A PORTFOLIO OF PRESCRIPTION AND OTC PRODUCTS IN AUSTRALIA TO MYLAN.MYLAN EXERCISED OPTION, TO BUY PORTFOLIO OF PRODUCTS FROM AGI AND ASPEN AUSTRALIA FOR A MAXIMUM CONSIDERATION OF AUD 188 MILLION.PROCEEDS FROM DEAL WILL BE USED TO REDUCE ASPEN'S GEARING.  Full Article

Aspen Pharmacare Says FY Normalised Headline Earnings From Cont Ops To Be In Line With H1 Pct Decline
Thursday, 7 Mar 2019 

March 7 (Reuters) - Aspen Pharmacare Holdings Ltd ::UNAUDITED INTERIM FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2018.EMBARKED ON A STRATEGIC REVIEW OF ITS EUROPEAN AND SOUTH AFRICAN COMMERCIAL PHARMACEUTICALS BUSINESSES.HY NHEPS 743 CENTS VERSUS 814 CENTS.HY REVENUE FROM CONTINUING. OPERATIONS 19.67 BILLION RAND VERSUS 19.51 BILLION RAND.DECIDED TO SPLIT S.AFRIC COMMERCIAL PHARMACEUTICALS INTO 2 DIVISIONS TO ACHIEVE HEIGHTENED PRODUCT AND CUSTOMER FOCUS.NORMALISED HEADLINE EARNINGS FROM CONTINUING OPERATIONS (AT CER) FOR FULL YEAR EXPECTED TO BE IN LINE WITH PERCENTAGE DECLINE RECORDED IN H1.CONVERSION RATE OF OPERATING PROFITS TO CASH OF BETWEEN 90% AND 100% IS ANTICIPATED FOR FULL FINANCIAL YEAR.CONCLUDED AGREEMENTS RELATING TO DIVESTMENT AND DISCONTINUATION OF NON-CORE PHARMACEUTICAL PORTFOLIO IN ASIA PACIFIC REGION.DIVIDEND OF 315 CENTS PER SHARE HAS BEEN PAID DURING HY (2017: 287 CENTS).  Full Article

Aspen Says Roy Andersen To Retire From Board
Thursday, 7 Mar 2019 

March 7 (Reuters) - Aspen Pharmacare Holdings Ltd ::JSE: APN - CHANGES TO THE BOARD AND ITS COMMITTEES.ASPEN PHARMACARE HOLDINGS LTD - APPOINTMENT OF THEMBA MKHWANAZI AND BEN KRUGER AS INDEPENDENT NON-EXECUTIVE DIRECTORS AND RETIREMENT OF ROY ANDERSEN.ASPEN PHARMACARE - ROY ANDERSEN HAS CONFIRMED THAT HE WILL, DUE TO TENURE CONSIDERATIONS, RETIRE FROM BOARD WITH EFFECT FROM 30 SEPTEMBER 2019.  Full Article

Aspen Pharmacare Holdings Reached Deal With Funders During Period To Nov
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN PHARMACARE HOLDINGS - CLARIFY THAT AGREEMENT WAS REACHED WITH ASPEN'S SYNDICATE OF FUNDERS DURING PERIOD TO NOV.ASPEN PHARMACARE HOLDINGS - DEAL PROVIDING MULTI-CURRENCY FACILITIES TO NEGOTIATE TEMPORARY ADJUSTMENT TO LEVERAGE RATIO COVENANT AS AT 31 DEC.  Full Article

Aspen On Track To Meet FY Guidance Of Commercial Pharma Organic Revenue Growth
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN PHARMACARE HOLDINGS LTD - ON TRACK TO MEET ITS FULL YEAR GUIDANCE OF COMMERCIAL PHARMA ORGANIC REVENUE GROWTH.ASPEN - FY GUIDANCE OF COMMERCIAL PHARMA ORGANIC REVENUE GROWTH RANGING BETWEEN 1% AND 4% BASED ON PERFORMANCE FOR FIVE MONTHS TO 30 NOVEMBER 2018.ASPEN - MANUFACTURING REVENUE FROM APIS HAS DONE BETTER THAN EXPECTED FOR FIVE MONTHS TO 30 NOVEMBER AND IS IN LINE WITH REVENUE FOR COMPARABLE PERIOD.ASPEN PHARMACARE - POSITIVE PERFORMANCE FROM COMMERCIAL PHARMA IN MOST EMERGING MARKETS, JAPAN OFFSET BY WEAKER PERFORMANCE IN EUROPE & RUSSIA IN FY.ASPEN PHARMACARE- SIGNIFICANT PROGRESS MADE IN PROCURING FULFILMENT OF CONDITIONS PRECEDENT TO DISPOSAL TO B.A.S. S.A. OF ASPEN'S NUTRITIONALS BUSINESS.  Full Article

Aspen Pharmacare Sells Global Nutritionals Business For EUR 739.8 Mln
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Aspen Pharmacare Holdings Ltd ::DIVESTMENT OF GLOBAL NUTRITIONALS BUSINESS TO LACTALIS FOR EUR739,8 MILLION.CONCLUDED AN AGREEMENT TO DIVEST OF ITS NUTRITIONALS BUSINESS TO LACTALIS GROUP.FY ASPEN IMPROVED REVENUE BY 3% TO R42,6 BILLION.FY NORMALISED HEADLINE EARNINGS PER SHARE BY 10% TO 1 605 CENTS.DEAL PROCEEDS OF EUR739,8 MILLION TO BE REDUCED BY EUR62 MILLION, WILL BE UTILISED TO BUY-OUT ASPEN'S JV PARTNERS IN NEW ZEALAND, CHINA.ANTICIPATED THAT DEAL WILL BE COMPLETED WITHIN SIX MONTHS OF SEPT. 13 ANNOUNCEMENT.STRONG OPERATING CASH FLOWS ARE ANTICIPATED TO CONTINUE.HAS DECLARED A GROSS DIVIDEND, WHICH IS PAID FROM INCOME RESERVES, OF 315 CENTS PER ORDINARY SHARE TO SHAREHOLDERS.  Full Article

Photo

South Africa's Aspen could supply 10 million dexamethasone pills in COVID-19 crisis

JOHANNESBURG South African pharmaceutical major Aspen could provide 10 million dexamethasone tablets within a month, Chief Executive Stephen Saad said on Tuesday after the World Health Organisation cautioned about the drug's supply.